AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
admin 19th August 2019 Uncategorised 0Drugs from the burgeoning JAK group have run into their fair share of safety liabilities, and if the label for new AbbVie med Rinvoq is any indication, the FDA now figures those problems extend to the entire class. That doesn’t bode well for up-and-comers—including Gilead’s closely watched filgotinib.
More: AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
Source: fierce